Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a biopharmaceutical company focused on medicines for genetic diseases, and its news flow reflects both commercial activity and clinical development progress. Company updates frequently highlight Attruby (acoramidis), a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Investors following BBIO news see regular disclosures on Attruby’s commercial performance and new clinical and real-world data from the ATTRibute-CM program and its open-label extension, including analyses of variant ATTR-CM populations and specific genetic subgroups. BridgeBio also reports on late-stage pipeline milestones, such as Phase 3 results for BBP-418 in LGMD2I/R9, topline data and regulatory plans for encaleret in autosomal dominant hypocalcemia type 1, and registrational studies of infigratinib in children with skeletal dysplasias.
News items often include participation in major medical and investor conferences, where BridgeBio presents moderated digital posters, scientific analyses, and corporate updates. Additional releases cover financial and corporate developments, including quarterly business updates, equity inducement grants, royalty monetization transactions related to acoramidis, and proposed offerings of convertible senior notes.
This BBIO news page on Stock Titan aggregates these announcements so readers can review clinical data disclosures, commercial updates, financing transactions, and governance developments in one place. For investors and observers tracking genetic disease drug development and ATTR-CM therapies, the news feed provides a concise view of BridgeBio’s reported progress and key events over time.
BridgeBio Pharma (Nasdaq: BBIO) presented groundbreaking data from the ATTRibute-CM study showing that acoramidis, their oral TTR stabilizer, demonstrates rapid efficacy in treating ATTR-CM (transthyretin amyloid cardiomyopathy). The drug showed significant cardiovascular benefits within the first month of treatment.
Key findings include a 49% hazard reduction in cardiovascular mortality or recurrent hospitalizations through Month 30 (p0.0001), with . At Month 42, continuous acoramidis treatment reduced cardiovascular mortality by 45% compared to placebo-to-acoramidis switch (p=0.0011).
Acoramidis, marketed as Attruby® in the US and BEYONTTRA® in Europe, Japan, and the UK, has received regulatory approval with labels specifying near-complete TTR stabilization.
BridgeBio Pharma (Nasdaq: BBIO) announced its upcoming participation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025 in Minneapolis from September 26-29. The company will present new data about Acoramidis for ATTR-CM treatment through five scientific presentations, including a late-breaking clinical trials session.
The presentations will cover various aspects of Acoramidis treatment, including its effects on cardiovascular outcomes, mortality rates, NT-proBNP levels, and cardiac conduction abnormalities in patients with transthyretin amyloid cardiomyopathy. Distinguished researchers from leading institutions will present the findings across oral and poster sessions.
BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company focused on genetic diseases, has announced several inducement grants of restricted stock units (RSUs) to new employees. The compensation committee approved RSU grants totaling 238,168 shares across 74 new employees between June and September 2025.
The RSU grants follow a consistent vesting schedule, with 25% of shares vesting after one year and the remaining shares vesting quarterly over the following three years, contingent on continued employment. These grants were made under the Company's Amended and Restated 2019 Inducement Equity Plan.
BridgeBio Pharma (Nasdaq: BBIO) announced positive Phase 2 proof-of-concept results for encaleret in treating post-surgical hypoparathyroidism. The study showed that 80% of participants achieved normal blood and urine calcium levels within 5 days of treatment, compared to 0% on conventional therapy.
The oral therapy demonstrated PTH-independent normalization of calcium levels, with nine participants showing rapid and sustained reduction in fractional excretion of calcium. The drug was well-tolerated with no serious adverse events reported. Based on these promising results, BridgeBio plans to initiate a registrational clinical study in 2026.
BridgeBio Pharma (Nasdaq: BBIO) announced an upcoming investor webinar scheduled for September 10, 2025, at 8:00 am ET. The webinar will feature Dr. Rachel Gafni, Senior Research Physician at the National Institute of Dental and Craniofacial Research (NIH) and Principal Investigator for the CALIBRATE Phase 3 trial.
The presentation will focus on autosomal dominant hypocalcemia type 1 (ADH1), including disease pathophysiology, unmet medical needs, and the potential of encaleret as a treatment. Executive team members will discuss the ongoing Phase 3 CALIBRATE study, with topline results expected in fall 2025.
BridgeBio Pharma (Nasdaq: BBIO) announced upcoming presentations at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025 in Seattle. The company will present Phase 2 data for encaleret in post-surgical hypoparathyroidism through an oral presentation by Dr. Iris Hartley from the National Institute of Dental and Craniofacial Research.
Additionally, two poster sessions focusing on skeletal dysplasia research will be presented by Dr. Bhavik Shah, showcasing data on infigratinib's effects on bone growth in hypochondroplasia and skull measures in Crouzon/Pfeiffer Syndromes mouse models.
BridgeBio Pharma (Nasdaq: BBIO) announced significant results from the ATTRibute-CM open label extension study of acoramidis through Month 42. The drug demonstrated a 44% reduction in cardiovascular mortality risk for patients with ATTR-CM. Additional key findings include a 46% hazard reduction in the composite outcome of cardiovascular mortality or first cardiovascular hospitalization.
The study showed that acoramidis, marketed as Attruby® in the US and BEYONTTRA® in Europe, achieved disease stabilization in about 50% of participants compared to less than 20% with placebo at Month 30, as measured by NT-proBNP levels. The drug demonstrated the fastest benefit observed in any Phase 3 ATTR-CM study to date, with results visible in just 3 months.
The data was presented at the European Society of Cardiology Congress 2025 in Madrid, highlighting acoramidis's potential as a transformative therapy for ATTR-CM patients.BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company focused on genetic diseases, has announced its participation in three major healthcare investor conferences in September 2025. The management team will host fireside chats at the Wells Fargo Healthcare Conference in Boston (September 3), the Cantor Global Healthcare Conference in New York (September 4), and the Morgan Stanley Global Healthcare Conference in New York (September 8).
Investors can access live webcasts of the presentations through BridgeBio's investor relations website, with replays available for 90 days following each event.
BridgeBio Pharma (Nasdaq: BBIO) announced its upcoming presentations at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The company will present additional open-label extension data from the ATTRibute-CM study through one oral presentation and two ePosters.
The presentations include data on cardiovascular mortality reduction at Month 42, NT-proBNP improvements at Month 30, and beneficial effects on NAC ATTR Stage changes. Key presenters include experts from Stanford University, UChicago Medicine, and University College London's Centre for Amyloidosis.
BridgeBio Pharma (Nasdaq: BBIO) reported strong Q2 2025 financial results, with total revenue of $110.6 million, including $71.5 million from Attruby® net product revenue. The company's flagship drug Attruby has gained significant traction with 3,751 unique patient prescriptions from 1,074 unique prescribers.
New analyses from the ATTRibute-CM study reinforced Attruby's clinical profile, showing a 59% relative risk reduction in variant ATTR-CM patients and a 31.6% relative risk reduction in mortality associated with increased TTR stabilization. The company ended Q2 with a strong cash position of $756.9 million.
BridgeBio expects multiple key Phase 3 trial results in fall 2025, including FORTIFY (BBP-418 for LGMD2I/R9) and CALIBRATE (encaleret for ADH1), with PROPEL 3 (infigratinib for achondroplasia) results expected in early 2026.